Riche issued EUA for new Anti-SARS-CoV-2 antibody test, Elecsys®
Category: #healthcare  By Mateen Dalal  Date: 2020-05-04
  • share
  • Twitter
  • Facebook
  • LinkedIn

Riche issued EUA for new Anti-SARS-CoV-2 antibody test, Elecsys®

Roche Holding AG, a multinational healthcare company, has recently been issued test with an EUA (Emergency Use Authorization) for its new Elecsys® Anti-SARS-CoV-2 antibody. This antibody test was designed to examine patients who have been exposed to the severe acute respiratory syndrome coronavirus 2 and in turn, have developed antibodies against this virus.

The company has started offering the test to the leading global laboratories and will scale its production capacity in a month to high double-digit millions. This will effectively cater to the healthcare systems in countries accepting the CE mark and the United States.

According to Severin Schwan, Roche Group’s CEO, the significant delivery of this antibody test in terms of quality and quantity can be attributed to the company’s dedicated team of employees. This test will aid healthcare systems in containing the coronavirus health crisis across the globe. He appreciated the efficacy of the test with high sensitivity and specificity, which is vital in assisting the healthcare professionals during the outbreak.

Thomas Schinecker, Roche Diagnostics’ CEO, stated that the company’s team of experts and scientists have worked efficiently over the last few months to form a highly reliable antibody test with an aim to fight against the COVID-19 pandemic. It is dedicated to assisting the laboratories in delivering reliable, fast, and accurate results to the healthcare systems.

The SARS-CoV-2 antibody test, with more than 99.8% specificity as well as sensitivity of 100% (14 days after confirmation of polymerase chain reaction), can help assess the immune response of the patient to the virus. Roche has extensive manufacturing capabilities globally and can deliver millions of tests in a month. Reference laboratories and hospitals can run the test on its cobas e analyzers that are available across the globe.

The local approval timelines will be applied for countries with various specific regulatory requirements. The availability of the test also depends on other country-specific regulations, including import requirements. In order to support the local registration efforts, it will closely work with the respective representatives in the region.

Source credit:

https://www.roche.com/media/releases/med-cor-2020-05-03.htm

About Author

Mateen Dalal    

Mateen Dalal

Despite working as a professional testing engineer, Mateen Dalal always held a liking for content creation. Following his passion, he now pens down articles for itresearchbrief.com and a couple of similar portals. Mateen is a qualified electronics and telecommunicat...

Read More>>

More News By Mateen Dalal

Ampio starts phase 1 clinical trial of Ampion for Covid-19 patients
Ampio starts phase 1 clinical trial of Ampion for Covid-19 patients
By Mateen Dalal

Ampio Pharmaceuticals Inc., the U.S-based biopharmaceutical firm focused on the development of novel...

Eon to use linguistics model to identify IPN and manage lung cancer
Eon to use linguistics model to identify IPN and manage lung cancer
By Mateen Dalal

Eon, a healthcare technology company, has announced the expansion of its data science models. The mo...

AE Industrial Acquires PCI; Adds New Government Tech Investment
AE Industrial Acquires PCI; Adds New Government Tech Investment
By Mateen Dalal

AE Industrial Partners (AEI), a private equity firm specializing in Defense, Aerospace & Governm...